drug
dabrafenib mesylate ODT
Marketedupdated 3mo agoby $NVS NOVARTIS AG
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.
all catalysts(40)
approval · 40
May 29, 2013
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Dec 26, 2013
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jan 9, 2014
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Aug 25, 2014
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Nov 20, 2015
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jun 16, 2016
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jun 16, 2017
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jun 22, 2017
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Apr 20, 2018
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Apr 30, 2018
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
May 4, 2018
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jul 16, 2019
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Oct 6, 2019
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Apr 9, 2020
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
May 7, 2021
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Dec 3, 2021
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jan 28, 2022
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Feb 4, 2022
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
May 27, 2022
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jun 22, 2022
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 16, 2023
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 16, 2023
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
May 26, 2023
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Aug 31, 2023
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Feb 27, 2024
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Feb 27, 2024
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 29, 2024
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 29, 2024
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jul 11, 2024
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jul 11, 2024
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jan 30, 2025
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jan 30, 2025
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 7, 2025
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 7, 2025
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 19, 2025
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 19, 2025
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Apr 7, 2025
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Apr 7, 2025
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 26, 2026
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 26, 2026
approval
$NVS160.31+3.73%
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Trials studying dabrafenib mesylate ODT
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 16, 2026
27 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (32)
- Dec 29, 2038patentUS 11504333*PED
- Jun 29, 2038formulationUS 11504333
- Feb 28, 2034patentUS 10869869*PED
- Feb 28, 2034patentUS 10869869*PED
- Aug 30, 2033method-of-use (U-3185)US 10869869
- Aug 30, 2033method-of-use (U-3185)US 10869869
- Apr 15, 2031patentUS 8703781*PED4.7y
- Apr 15, 2031patentUS 8703781*PED4.7y
- Apr 15, 2031patentUS 8703781*PED4.7y
- Apr 15, 2031patentUS 8952018*PED4.7y
- Apr 15, 2031patentUS 8952018*PED4.7y
- Oct 15, 2030compositionUS 87037814.2y
- Oct 15, 2030compositionUS 87037814.2y
- Oct 15, 2030compositionUS 87037814.2y
- Oct 15, 2030method-of-use (U-2027)US 89520184.2y
- Oct 15, 2030method-of-use (U-2027)US 89520184.2y
- Jul 20, 2030patentUS 7994185*PED3.9y
- Jul 20, 2030patentUS 7994185*PED3.9y
- Jul 20, 2030patentUS 7994185*PED3.9y
- Jul 20, 2030patentUS 8415345*PED3.9y
- Jul 20, 2030patentUS 8415345*PED3.9y
- Jul 20, 2030patentUS 8415345*PED3.9y
- Jan 20, 2030compositionUS 79941853.4y
- Jan 20, 2030compositionUS 79941853.4y
- Jan 20, 2030compositionUS 79941853.4y
- Jan 20, 2030compositionUS 84153453.4y
- Jan 20, 2030compositionUS 84153453.4y
- Jan 20, 2030compositionUS 84153453.4y
- Nov 4, 2029patentUS 9233956*PED3.2y
- Nov 4, 2029patentUS 9233956*PED3.2y
- May 4, 2029method-of-use (U-1811)US 92339562.7y
- May 4, 2029method-of-use (U-2032)US 92339562.7y
FDA exclusivities (12)
- Sep 16, 2030PEDPediatric (6mo bonus)4.1y
- Sep 16, 2030PEDPediatric (6mo bonus)4.1y
- Sep 16, 2030PEDPediatric (6mo bonus)4.1y
- Mar 16, 2030ODE-428Orphan Drug (7y)3.6y
- Mar 16, 2030ODE-428Orphan Drug (7y)3.6y
- Mar 16, 2030ODE-428Orphan Drug (7y)3.6y
- Sep 16, 2026PEDPediatric (6mo bonus)27d
- Sep 16, 2026PEDPediatric (6mo bonus)27d
- Sep 16, 2026PEDPediatric (6mo bonus)27d
- Mar 16, 2026I-908Indication (3y)
- Mar 16, 2026NPNP
- Mar 16, 2026I-908Indication (3y)
News(1)
- Labcorp nabs FDA green light for BRAF melanoma diagnosticThe FDA has signed off on Labcorp’s companion diagnostic for patients with advanced melanoma carrying certain BRAF variants.fiercebiotech · 9d ago
Data sources
last refreshed 49m ago
Found something off?
comments(0)
5-min edit window · permanent after that